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Objectives: The risk of stroke is increased in patients with bipolar
disorder. Lithium exhibits neuroprotective effects but the association
between lithium use and the risk of stroke is unknown.
Methods: A population-based retrospective cohort study was conducted
by utilizing the National Health Insurance Research Database in
Taiwan. Subjects who had first been diagnosed with bipolar disorder
between 2001 and 2006 were identified. A propensity score (PS) for
receiving lithium was calculated with variables of age, gender, and
comorbidities. The patients with bipolar disorder receiving lithium
within the period from diagnosis through to December 2011 were
designated as the lithium group (n = 635). A 1:2 ratio was used to select
PS-matched subjects with bipolar disorder without lithium use
(n = 1,250). Multivariate Cox proportional hazards regression models
were used to explore the association, rather than causal inference, of
lithium exposure and the risk of stroke.
Results: Of the 1,885 subjects, 86 (4.6%) experienced stroke, including
2.8% of the lithium group and 5.4% of the non-lithium group. Lithium
use was associated with a significantly reduced risk of stroke [hazard
ratio (HR) = 0.39, 95% confidence interval (CI): 0.22–0.68]. Reduced
risks of stroke were also associated with the highest cumulative lithium
dose [≥720 defined daily dose (DDD), HR = 0.25, 95% CI: 0.10–0.59],
the longest cumulative exposure period (≥720 days, HR = 0.20, 95% CI:
0.06–0.64), and the highest exposure rate (≥2 DDD/day, HR = 0.39,
95% CI: 0.21–0.70).
Conclusions: Lithium use was significantly related to a reduced risk of
stroke in patients with bipolar disorder.
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Stroke is one of the most severe medical conditions
and it has been reported to account for 5.5 million
deaths and 44 million disability-adjusted life-years
lost worldwide annually (1). Previous studies have
demonstrated an increased risk of stroke of up to
twofold among patients with bipolar disorder
(2–4). However, the possible effects of medication
on the risk of stroke were not further analyzed in
these studies. Lithium was first suggested as a
treatment for ‘psychotic excitement’ in 1949 (5)
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BIPOLAR DISORDERS
and its efficacy in the management of bipolar disor-
der was established in the 1970s (6). In addition,
lithium has been shown to increase neuronal den-
sity and gray matter volume in patients with bipo-
lar disorder (7, 8).
In vitro and in vivo animal studies have demon-
strated multiple neurotrophic and neuroprotective
effects of lithium (9). The principal mechanisms
underlying lithium’s neuroprotective effects are as
follows. (i) Inhibition of glycogen synthase kinase-
3 (GSK-3), an enzyme linked to apoptosis induced
by various neural insults (10). In animal stroke
models, GSK-3b was found to be upregulated, and
its inhibition by lithium was implicated as an
important neuroprotective mechanism (11). (ii)
Induction of brain-derived neurotrophic factor
(BDNF), which plays a key role in neuronal devel-
opment, plasticity, and survival (12). (iii) Increased
expression of vascular endothelial growth fac-
tor (VEGF), which induces neuronal prolifera-
tion and neurovascular remodeling (13). (iv)
Inhibition of N-methyl–D-aspartate (NMDA)
receptor-mediated calcium influx and downstream
apoptotic pathways, resulting in decreased gluta-
mate excitotoxicity (14). (v) Inhibition of phospho-
inositol phosphatase and regulation of autophagy
(15), a critical process for neuronal survival and
functioning.
Animal studies have also shown that lithium
reduces neuronal injury after various insults,
including ischemia (16–18), hemorrhage (19), and
trauma (20). However, only one human study has
investigated the neuroprotective effects of lithium
after stroke, and the results were inconclusive, in
that only the subgroup of patients with cortical
ischemic stroke showed enhanced motor recovery
with lithium treatment (21).
It is still unclear whether lithium has any effect
on the susceptibility to cerebrovascular disease.
The progression from atherosclerotic plaque for-
mation to plaque rupture and ischemic stroke is
driven by inflammation, extracellular matrix
degradation, and neovascularization (22). Macro-
phages play an important role in the inflammatory
process of atherosclerosis. In an animal study,
lithium chloride induced macrophage apoptosis
via inhibition of inositol monophosphatase (23).
Lithium also reduced the expression of vascular
cell adhesion molecule (VCAM)-1 and the infiltra-
tion of macrophages into the atherosclerotic pla-
que (24). This, in turn, decreased the macrophage
load within the atherosclerotic plaques and impli-
cated a plaque-stabilizing effect exhibited by
lithium. Metalloproteinases participated in the ini-
tiation, progression, and rupture of atherosclerotic
plaque and the formation of thrombus (25). Matrix
metalloproteinase (MMP)-9 was associated with
abnormal degradation of the extracellular matrix
when its production by macrophages was deregu-
lated. Lithium treatment was found to suppress
MMP-9 gene expression and reduce the level of
this metalloproteinase (26), thereby reducing pla-
que instability. Vascular smooth muscle cell
(VSMC) proliferation and migration in the intima
of the arterial wall also play an important role in
atheroma progression (27). VSMCs are also
important mediators of abnormal neovasculariza-
tion in the atherosclerotic plaque which expedites
the process toward plaque rupture (28). Lithium
inhibited VSMC proliferation and migration in an
animal study (29). It also reduced blood glucose
and cholesterol levels in mice fed a high-fat diet
(24) and this may alleviate the detrimental effects
of diabetes or hyperlipidemia on stroke events.
The above mechanisms contribute to the beneficial
effect of lithium on atherosclerosis and cerebral
ischemia.
Lithium treatment has been demonstrated dra-
matically to reduce atherosclerotic plaque forma-
tion in mice (24). Another animal study discovered
that the combination of low-dose lithium with cap-
topril prevented stroke and improved survival in
salt-loaded, stroke-prone spontaneously hyperten-
sive rats, an animal model for cerebrovascular dis-
ease (30). However, no study has focused on the
effect of lithium on the risk of stroke in human
populations. If lithium were consistently to demon-
strate neurotrophic and neuroprotective effects,
this could be translated into clinical benefits for
central nervous system disorders such as stroke,
and would have significant implications for
patients at risk of stroke and other cerebral insults.
We conducted a retrospective cohort study by
analyzing a population-based dataset from the
National Health Insurance Research Database in
Taiwan. The aim was to determine whether lithium
is related to the susceptibility to stroke and its
occurrence in patients with bipolar disorder.
Methods
Database
The National Health Research Institutes (NHRI),
Taiwan, maintain the National Health Insurance
Research Database (NHIRD) for research pur-
poses. We obtained a subset of the NHIRD with
1,000,000 random subjects, which accounted for
about 5% of all enrollees in the National Health
Insurance program. The random sampling pro-
cess from the NHIRD to yield the 1,000,000-
subject database was performed by the NHRI and
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including the following main steps: (i) a serial num-
ber was assigned to each of the 23,251,700 subjects
in the original population; (ii) a random number
generator was used to generate 1,000,000 random
numbers; (iii) the subjects, with their serial number
matching the generated random numbers, were
selected to form the database subset (31). There
were no statistically significant differences in age,
gender, or costs between the sample group and all
other enrollees. The database contained informa-
tion about medical claims for ambulatory care,
inpatient care, dental services, and prescription
drugs as well as registration files of the enrollees,
insured from January 1996 to December 2011. The
International Classification of Diseases, Ninth
Revision (ICD-9) diagnostic system was incorpo-
rated into the data since the year 2000.
Study design
The current study was an 11-year retrospective
cohort study from January 1, 2001 to December 31,
2011. Subjects newly diagnosed with bipolar disor-
der (i.e., ICD-9 codes: 296.0, 296.1, 296.4–296.9 in
three or more outpatient visits or any inpatient hos-
pitalization records) within the interval of January
1, 2001 through to December 31, 2006 were first
identified. The subjects were excluded if they had
any diagnosis of stroke before the diagnosis of bipo-
lar disorder. The patients with bipolar disorder were
further divided into the lithium group and the non-
lithium group, depending on lithium exposure from
the prescription record. The lithium group and the
non-lithium group, comprised the unmatched
cohort in our study.
As the patients with bipolar disorder in the study
were not randomly assigned to lithium treatment,
we further utilized a propensity score (PS) to
reduce potential confounding and selection biases.
A multivariate logistic regression model was gener-
ated to predict the probability of receiving lithium,
given the following set of covariates: age, gender,
and comorbidities including diabetes mellitus,
hypertension, hyperlipidemia, coronary artery dis-
ease, and chronic kidney disease. A PS was calcu-
lated for each subject and subsequently utilized to
match the lithium group with the non-lithium
group at a ratio of 1:2. Both the unmatched cohort
and the PS-matched cohort were analyzed. The
endpoints of the follow-up were the occurrences of
the first stroke event (after lithium exposure in the
lithium group), death, or end of study, on Decem-
ber 31, 2011.
To clarify further the association between
lithium exposure and the risk of stroke in patients
with bipolar disorder, we utilized three indexes –
the cumulative lithium dose, the cumulative
lithium exposure period, and the lithium exposure
rate – to describe these specific characteristics in
the PS-matched cohort. The cumulative lithium
dose of each subject was represented by the num-
ber of cumulative defined daily dose (DDD) of
lithium. This value was acquired by dividing the
total lithium dosage during the study period by the
DDD of lithium (one DDD equals 24 mmol of
lithium). The cumulative lithium dose was strati-
fied into five subgroups: no use, <60 DDD, 60–359
DDD, 360–719 DDD, and ≥720 DDD. The cumu-
lative lithium exposure period was the sum of the
number of days for which each subject was pre-
scribed lithium; it was stratified into five sub-
groups: no use, <60 days, 60–359 days, 360–
719 days, and ≥720 days. The lithium exposure
rate was the ratio of the cumulative lithium dose
divided by the cumulative lithium exposure period;
it was stratified into four subgroups: 0 DDD/day,
<1 DDD/day, 1–2 DDD/day, ≥2 DDD/day.
Definition of stroke and comorbidities
The stroke diagnosis was defined by ICD-9 codes
430–438 (ischemic: 433–437, hemorrhagic: 430–
432) in any inpatient or three or more outpatient
treatments during the study period. Patients who
had a diagnosis of transient ischemic attack (ICD-
9 code: 435) were excluded. Comorbidities in the
12-month period prior to the diagnosis of bipolar
disorder, including diabetes mellitus (ICD-9 code:
250), hypertension (code: 401–405), hyperlipidemia
(code: 272), chronic kidney disease (code: 585),
coronary artery disease (code: 410–413), and con-
gestive heart failure (code: 428), were confirmed by
any inpatient or two or more outpatient treatments
for the diagnoses in the NHI records.
Statistical analysis
Distributions of lithium users and non-users in
terms of age, gender, clinical comorbidities, use of
typical antipsychotic agents, use of atypical
antipsychotic agents, use of mood stabilizers
including valproate and carbamazepine, and stroke
were examined using Student t-tests for continuous
variables and chi-square tests for categorical vari-
ables. Multivariate Cox proportional hazards
regression models were used in both the
unmatched cohort and the PS-matched cohort to
explore the relationship between lithium exposure
and the occurrence of stroke, adjusted for age, gen-
der, comorbidities, use of antipsychotic agents,
and use of mood stabilizers. Three additional Cox
proportional hazards regression models were
707
Lithium reduces risk of stroke in bipolar disorder
implemented in the PS-matched cohort. Model 1
was adjusted for age, gender, comorbidities, use of
antipsychotic agents, use of mood stabilizers, and
the cumulative lithium dose. Model 2 was adjusted
for age, gender, comorbidities, use of antipsychotic
agents, use of mood stabilizers, and the cumulative
lithium exposure period. Model 3 was adjusted for
age, gender, comorbidities, use of antipsychotic
agents, use of mood stabilizers, and the lithium
exposure rate. The proportional hazard assump-
tions were satisfied by testing graphically and by
including the interaction of time with each covari-
ate in the Cox regression models. The stroke-free
survival curves of the lithium group and non-
lithium group of both the unmatched cohort and
the PS-matched cohort were plotted with the pro-
duct-limit survival estimators for stroke. All statis-
tical tests were two-sided, conducted at a
significance level of 0.05, and reported using p val-
ues and 95% confidence intervals. All analyses
were performed using the SAS software, version
9.1 (SAS Institute, Cary, NC, USA).
Results
Data for a total of 3,681 subjects in the unmatched
cohort and 1,885 subjects in the PS-matched
cohort during the observation period from 2001 to
2011 were analyzed. The lithium group of the
unmatched cohort was younger, consisted of more
male subjects, and had significantly lower rates of
diabetes mellitus, hypertension, hyperlipidemia,
and coronary artery disease compared to the non-
lithium group and had no cases of chronic kidney
disease (Table 1). By contrast, the PS-matching
process successfully removed these differences in
the PS-matched cohort. The lithium group in the
PS-matched cohort was not significantly different
in terms of age, gender, and comorbidities com-
pared to the non-lithium group (Table 1). Of note,
none of the subjects in the PS-matched cohort had
chronic kidney disease. The rates of use of typical
antipsychotic agents, atypical antipsychotic agents,
and mood stabilizers were all significantly lower in
the non-lithium group compared to the lithium
group in both the unmatched and the PS-matched
cohort.
Among the total sample of 3,681 subjects in the
unmatched cohort, 325 (8.8%) had stroke, includ-
ing 18 (2.8%) among the lithium group and 307
(10.1%) among non-users. Among the 1,885 sub-
jects in the PS-matched cohort, 86 (4.6%) had
stroke, including 18 (2.8%) among the lithium
group and 68 (5.4%) among non-users.
As shown in Table 2, after adjusting for possi-
ble confounders by using the multivariate Cox
proportional hazards regression model, lithium
users in the unmatched cohort were associated
with a significantly lower risk of stroke compared
to non-users [hazard ratio (HR) = 0.43, p =
0.0010]. The age-related risk of stroke was 1.06
times per decade older (HR = 1.06, p < 0.0001).
An increased risk of stroke was also associated
with male gender (HR = 1.32, p = 0.0130), dia-
betes mellitus (HR = 1.87, p < 0.0001), hyperten-
sion (HR = 1.45, p = 0.0055), and mood-stabilizer
use (HR = 1.54, p = 0.008). Neither typical
(HR = 0.95, p = 0.6784) nor atypical (HR = 1.05,
p = 0.6992) antipsychotic agent use was signifi-
cantly associated with the risk of stroke.
In the PS-matched cohort, the lithium group
also had a significantly reduced risk of stroke com-
pared to non-users (HR = 0.39, p = 0.0010). The
age-related risk of stroke was 1.07 times per decade
older (HR = 1.07, p < 0.0001). No comorbidities
were shown to be associated with the risk of stroke
in the PS-matched cohort. Neither typical
(HR = 0.81, p = 0.4392) nor atypical (HR = 1.32,
p = 0.2792) antipsychotic agent use was signifi-
cantly associated with the risk of stroke. The use of
mood stabilizers was associated with an increased
risk of stroke in this cohort (HR = 2.23,
p = 0.0017).
The risk of stroke associated with different levels
of lithium exposure among the PS-matched cohort
is listed in Table 3. A significantly reduced risk of
stroke was demonstrated in the subgroup with a
cumulative lithium dose ≥720 DDD (HR = 0.25,
p < 0.01), the subgroups with a cumulative lithium
exposure period of 60–359 days (HR = 0.35,
p < 0.05) and ≥720 days (HR = 0.20, p < 0.01),
and the subgroup with the lithium exposure rate of
≥2 DDD/day (HR = 0.39, p < 0.05).
The stroke-free survival curves of the lithium
and non-lithium groups in the unmatched and PS-
matched cohorts are shown in Figures 1 and 2,
respectively. The stroke-free survival probabilities
were significantly lower in the non-lithium group
in both the unmatched cohort and the PS-matched
cohort (p < 0.0001 and p = 0.0080, respectively).
The HRs within each subsequent year during the
study period are also marked in the Figures 1 and
2. The HRs for stroke associated with lithium use
reached statistical significance in the seventh and
eighth year of follow-up in the unmatched cohort
and the PS-matched cohort, respectively.
Discussion
The current study showed that lithium treatment is
significantly associated with a reduced risk of
stroke in patients with bipolar disorder. The
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association appeared to be most prominent with a
greater amount or longer duration of lithium treat-
ment. Significantly reduced risks of stroke were
observed in the subgroups with the highest cumu-
lative lithium dose, the longest cumulative lithium
exposure period, and the highest lithium exposure
rate. This indicated that the dose, duration, and
rate of lithium exposure might be related to the
risk of stroke in patients with bipolar disorder.
Around 93% of the stroke cases in the PS-
matched cohort were of ischemic origin. Addi-
tional analysis revealed that the HR of ischemic
stroke associated with lithium use in the PS-
matched cohort was 0.40 [95% confidence interval
(CI): 0.22–0.71, p = 0.0019] after adjusting for age,
gender, and related confounders. Lithium might
alter the process of atherosclerosis via its effect on
inflammation, extracellular matrix degradation,
and neovascularization.
Our findings that age, male gender, diabetes mel-
litus, and hypertension are associated with an
increased risk of stroke in patients with bipolar dis-
order were compatible with two previous studies
similarly focusing on patients with bipolar disorder
(2, 3). Of note, our finding that female gender was
associated with a reduced risk of stroke was consis-
tent with these two studies but the underlying
mechanism is not well understood. Lin et al. (3)
also pointed out that renal disease was a risk factor
for stroke. However, lithium treatment is generally
avoided in patients with severe renal disease, owing
to a heightened risk of toxicity (32). None of the
635 patients with bipolar disorder in the lithium
group in the current study had chronic kidney
Table 1. Characteristics of study participants
Variables
Unmatched cohort PS-matched cohort
Without lithium With lithium
p-value
Without lithium With lithium
p-value(n = 3,046) (n = 635) (n = 1,250) (n = 635)
Age, years, mean  SD 44.5  17.2 36.0  13.7 <0.0001 37.0  14.3 36.0  13.7 0.1610
Gender, n (%)
Female 1,800 (59.1) 335 (52.8) 0.0030 692 (55.4) 335 (52.8) 0.2830
Male 1,246 (40.9) 300 (47.2) 558 (44.6) 300 (47.2)
Diabetes mellitus, n (%)
No 2,849 (93.5) 624 (98.3) <0.0001 1,232 (98.6) 624 (98.3) 0.6260
Yes 197 (6.5) 11 (1.7) 18 (1.4) 11 (1.7)
Hypertension, n (%)
No 2,561 (84.1) 602 (94.8) <0.0001 1,185 (94.8) 602 (94.8) 0.9980
Yes 485 (15.9) 33 (5.2) 65 (5.2) 33 (5.2)
Hyperlipidemia, n (%)
No 2,886 (94.7) 621 (97.8) 0.0010 1,221 (97.7) 621 (97.8) 0.8740
Yes 160 (5.3) 14 (2.2) 29 (2.3) 14 (2.2)
Chronic kidney disease, n (%)
No 3,017 (99.1) 635 (100) 0.0140 – – –
Yes 29 (0.9) 0 (0) – – –
Coronary artery disease, n (%)
No 2,882 (94.6) 625 (98.4) <0.0001 1,233 (98.6) 625 (98.4) 0.7110
Yes 164 (5.4) 10 (1.6) 17 (1.4) 10 (1.6)
Congestive heart failure, n (%)
No 3,004 (98.6) 630 (99.2) 0.2270 1,243 (99.4) 630 (99.2) 0.5520
Yes 42 (1.4) 5 (0.8) 7 (0.6) 5 (0.8)
Typical antipsychotic agents, n (%)
No 882 (29.0) 72 (11.3) <0.0001 338 (27.0) 72 (11.3) <0.0001
Yes 2,164 (71.0) 563 (88.7) 912 (73.0) 563 (88.7)
Atypical antipsychotic agents, n (%)
No 1,855 (60.9) 150 (23.6) <0.0001 727 (58.2) 150 (23.6) <0.0001
Yes 1,191 (39.1) 485 (76.4) 523 (41.8) 485 (76.4)
Mood stabilizers, n (%)
No 1,949 (64.0) 180 (28.3) <0.0001 742 (59.4) 180 (28.3) <0.0001
Yes 1,097 (36.0) 455 (74.7) 508 (40.6) 455 (74.7)
Incident stroke events, n (%)
No 2,739 (89.9) 617 (97.2) 0.0030 1,182 (94.6) 617 (97.2) 0.0100
Yes 307 (10.1) 18 (2.8) 68 (5.4) 18 (2.8)
PS = propensity score; SD = standard deviation.
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disease. This reflected the extreme precaution taken
by doctors when prescribing lithium to patients
with bipolar disorder and renal dysfunction.
By implementing PS matching, we successfully
removed the differences in comorbidities between
the original groups of patients with bipolar disor-
der. In the unmatched cohort, the subjects in the
non-lithium group were significantly older and had
a higher prevalence of diabetes mellitus, hyperten-
sion, hyperlipidemia, coronary artery disease, and
chronic kidney disease, each of which alone was a
risk factor for stroke (33, 34). This potentially may
have caused an overestimation of the association
between lithium exposure and the reduced risk of
stroke as the lithium group had significant fewer
risk factors at baseline. The finding that the risk of
stroke remained significantly reduced in associa-
tion with the lithium group in the PS-matched
cohort strengthened our findings.
Psychiatric disorders such as depression (35) and
schizophrenia (36) are also associated with a higher
risk of stroke. Lithium may be used as an adjunc-
tive treatment for subjects with mood swings or
those at risk of suicide in these psychiatric patient
groups. There is a possibility that lithium alters the
risk of stroke in such patients but our results could
not be extrapolated to subjects beyond the bipolar
disorder group.
Various psychotropic agents may also alter the
risk of stroke. No previous studies have focused on
the association between medication use and the
risk of stroke in patients with bipolar disorder. In
our analyses of the unmatched cohort and the PS-
matched cohort, we adjusted for the use of both
typical and atypical antipsychotic agents, which
were not associated with the risk of stroke
in patients with bipolar disorder. From studies
targeting other disease populations, such as those
with schizophrenia and dementia, the risk of stroke
associated with the use of antipsychotic agents was
found to be equivocal. Some studies reported no
association between the use of either typical or
atypical antipsychotic agents and the risk of stroke
(37), whereas others reported that the use of typical
antipsychotic agents was associated with an
increased risk of stroke (38–40), and still others
reported this association for atypical antipsychotic
agents (41). This finding of no significant associa-
tion may also be related to the distinctive effects of
different individual antipsychotic agents on the risk
of stroke. In addition, we found that the use of
mood stabilizers was associated with an increased
risk of stroke. No previous studies have evaluated
the association between the risk of stroke and use
of mood stabilizers in patients with bipolar disor-
der. However, in previous epilepsy studies, in
which the mood stabilizers we used in the current
study were used as anticonvulsants, a similarly
increased risk of stroke associated with anticonvul-
sants use was demonstrated (42, 43). Further stud-
ies, with a broader range of subjects and a detailed
differentiation of prescribed medication, are
needed to fully delineate the effect of lithium treat-
ment on the risk of stroke.
Strengths and limitations
One of the strengths of the current study was the
use of the NHIRD, which included diagnostic cod-
ing and records of prescribed medication in detail.
Lithium is a medication with clear clinical indica-
tions; we therefore considered the records of
lithium prescriptions to be valid and reliable. The
database also provided a sample with a large
Table 2. Multivariate Cox proportional analyses for hazard ratio of stroke
Variables
Unmatched cohort PS-matched cohort
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Lithium 0.43 (0.26–0.71) 0.0010 0.39 (0.22–0.68) 0.0010
Age (10 years) 1.06 (1.05–1.07) <0.0001 1.07 (1.06–1.09) <0.0001
Gender (male/female) 1.32 (1.06–1.65) 0.0130 1.50 (0.98–2.32) 0.0639
Diabetes mellitus 1.87 (1.37–2.54) <0.0001 2.60 (0.87–7.78) 0.0872
Hypertension 1.45 (1.12–1.89) 0.0055 1.56 (0.86–2.84) 0.1458
Hyperlipidemia 0.85 (0.57–1.26) 0.4139 0.70 (0.20–2.41) 0.5659
Chronic kidney disease 0.96 (0.42–2.19) 0.9125 – –
Coronary artery disease 1.15 (0.82–1.61) 0.4114 1.29 (0.49–3.39) 0.6002
Congestive heart failure 0.62 (0.27–1.42) 0.2599 0.59 (0.08–4.40) 0.6082
Typical antipsychotic agents 0.95 (0.74–1.22) 0.6784 0.81 (0.48–1.37) 0.4392
Atypical antipsychotic agents 1.05 (0.82–1.34) 0.6992 1.32 (0.80–2.19) 0.2792
Mood stabilizers 1.54 (1.19–1.97) 0.0008 2.23 (1.35–3.67) 0.0017
CI = confidence interval; PS = propensity score.
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number of subjects, allowing for analysis with
strong statistical power. We focused on lithium use
among people with bipolar disorder, thereby
avoiding the bias of use by indication. PS matching
and Cox proportional hazards regression models
minimized possible confounding effects. In addi-
tion, the present study was the first to take into
consideration of the use of psychotropic medica-
tions when analyzing the risk of stroke in patients
with bipolar disorder.
There were several limitations in the current
study. One of the most important of these was that
Table 3. Adjusted hazard ratios (HR) of lithium dosage or duration of stroke in PS-matched cohort
Variables n
Model 1 Model 2 Model 3
Adjusted
HR 95% CI
Adjusted
HR 95% CI
Adjusted
HR 95% CI
Age (10 years) 1.07 1.06–1.09a 1.07 1.06–1.09a 1.07 1.06–1.09a
Gender 1.51 0.98–2.33 1.52 0.99–2.35 1.48 0.96–2.27
Male 858
Female 1,027
Cumulative lithium dose
No use 1,250 1.00 Reference
<60 DDD 86 0.61 0.19–1.98
60–359 DDD 151 0.49 0.19–1.24
360–719 DDD 75 0.58 0.20–1.63
≥720 DDD 323 0.25 0.10–0.59b
Cumulative lithium exposure
period
No use 1,250 1.00 Reference
<60 days 179 0.70 0.33–1.48
60–359 days 181 0.35 0.14–0.88c
360–719 days 79 0.36 0.09–1.51
≥720 days 196 0.20 0.06–0.64b
Lithium exposure rate
0 DDD/day 1,250 1.00 Reference
<1 DDD/day 24 1.05 0.24–4.58
1–2 DDD/day 67 0.19 0.03–1.41
≥2 DDD/day 544 0.39 0.21–0.70c
Diabetes mellitus 2.65 0.88–7.98 2.62 0.87–7.87 2.70 0.89–8.13
Yes 29
No 1,856
Hypertension 1.54 0.85–2.81 1.54 0.85–2.82 1.53 0.84–2.80
Yes 98
No 1,787
Hyperlipidemia 0.66 0.19–2.28 0.67 0.19–2.29 0.68 0.19–2.39
Yes 43
No 1,842
Coronary artery disease 1.32 0.50–3.48 1.28 0.49–3.38 1.26 0.48–3.33
Yes 27
No 1,858
Congestive heart failure 0.54 0.07–4.09 0.52 0.07–4.03 0.52 0.07–3.98
Yes 12
No 1,873
Typical antipsychotic agent 0.82 0.49–1.38 0.81 0.48–1.37 0.81 0.48–1.37
Yes 1,475
No 410
Atypical antipsychotic agent 1.31 0.79–2.18 1.34 0.81–2.21 1.32 0.79–2.19
Yes 1,008
No 877
Mood stabilizers 2.27 1.38–3.72b 2.28 1.39–3.74b 2.23 1.35–3.67b
Yes 963
No 922
CI = confidence interval; DDD = defined daily dose; PS = propensity score.
ap < 0.001.
bp < 0.01.
cp < 0.05.
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the study design precluded causal inference, so the
associations between lithium use and reduced risk
of stroke should be interpreted with caution. In
addition, because of the lack of information in
NHIRD records of other possible risk factors for
stroke, such as body mass index, cigarette smok-
ing, and alcohol consumption, the current study
could not control for these confounders. Due to
the fact that lithium was rarely prescribed for
patients with severe renal dysfunction, and that the
lithium group in our cohorts contained no patients
with chronic kidney disease, the results could not
be extrapolated to patients with bipolar disorder
with chronic kidney disease. Finally, the results
should not be generalized to patients receiving
lithium treatment for conditions other than bipolar
disorder.
Conclusions
Lithium use may be associated with a reduced risk
of stroke in patients with bipolar disorder. This
association may be strongest among patients with
bipolar disorder receiving a higher dose, longer
duration, and higher rate of lithium exposure. In
clinical practice, the prevention of stroke by moni-
toring and early intervention for relevant cere-
brovascular risk factors is of paramount
importance for patients with bipolar disorder as
this condition is itself a risk factor for stroke.
Lithium treatment in patients with bipolar disorder
may be a reasonable choice if the patient does not
have chronic kidney disease. The duration or tim-
ing of discontinuation of lithium treatment may
influence the association with the risk of stroke. As
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Fig. 1. The product-limit survival estimates for stroke in the unmatched cohort. aHazard ratio. *p < 0.50, **p < 0.01.
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Fig. 2. The product-limit survival estimates for stroke in the propensity score-matched cohort. aHazard ratio. *p < 0.50.
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the design of the current study precluded causal
inference, future studies are indicated to clarify
whether lithium exerts a protective effect on stroke
and the possible underlying mechanisms if such a
protective effect exists.
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